{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"48.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from randomization to death from any cause.","groups":[{"description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Alectinib"},{"description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG001","title":"Crizotinib"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From randomization until death (up to 10.5 years)","title":"Percentage of Participants With OS Event","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}